Actinogen Limited Announces Ethical Approval of Xanamem in Phase I Trial for Alzheimer’s Disease

Actinogen Limited Announces Ethical Approval of Xanamem in Phase I Trial for Alzheimer’s Disease
Actinogen Limited, a biotechnology company focused on the treatment of Alzheimer’s Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer’s and dementia, recently announced that it has received approval for the third and final stage of the second Phase I trial of its lead Alzheimer’s

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *